Literature DB >> 2961436

Presence of somatomedin receptors on primary human breast and colon carcinomas.

M N Pollak1, J F Perdue, R G Margolese, K Baer, M Richard.   

Abstract

Competitive binding techniques were used to study the interaction of insulin-like growth factor I (IGF-I) with a plasma membrane-enriched subcellular fraction purified from primary breast and colon carcinoma specimens obtained at surgery. The presence of specific binding sites for IGF-I was detected in all tumour specimens studied. Scatchard analysis and competition studies with insulin and insulin-like growth factor-II (IGF-II) revealed the presence of specific IGF-I receptors, showing a Kd-value of approximately 2 nM. These results are consistent with the hypothesis that somatomedins play a role in determining the proliferative behaviour of human breast and colon tumors, and suggest that recent laboratory studies showing dependence of neoplastic cells on somatomedins for optimum proliferation may have clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961436     DOI: 10.1016/0304-3835(87)90218-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  31 in total

1.  Is diabetes a risk factor for colorectal cancer?

Authors:  Hamed Khalili; Andrew T Chan
Journal:  Dig Dis Sci       Date:  2012-04-25       Impact factor: 3.199

Review 2.  Diabetes mellitus is an independent risk factor for colorectal cancer.

Authors:  Lei Sun; Shiying Yu
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

Review 3.  Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions.

Authors:  Jeffrey A Meyerhardt
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

Review 4.  Roles of hormones and signaling molecules in describing the relationship between obesity and colon cancer.

Authors:  Angelos K Sikalidis; Behzad Varamini
Journal:  Pathol Oncol Res       Date:  2011-01-09       Impact factor: 3.201

5.  A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Authors:  Juergen M Schanzer; Katharina Wartha; Rebecca Croasdale; Samuel Moser; Klaus-Peter Künkele; Carola Ries; Werner Scheuer; Harald Duerr; Sandra Pompiati; Jan Pollman; Jan Stracke; Wilma Lau; Stefan Ries; Ulrich Brinkmann; Christian Klein; Pablo Umana
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

6.  IGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report.

Authors:  Adam Kuklinski; Zbigniew Kamocki; Mariusz Koda; Zdzislaw Piotrowski; Stanislaw Sulkowski; Ryszard Lesniewicz; Krystyna Pawlak; Piotr Mysliwiec; Boguslaw Kedra
Journal:  Oncol Lett       Date:  2011-08-29       Impact factor: 2.967

7.  Molecular imaging of insulin-like growth factor 1 receptor in cancer.

Authors:  Yin Zhang; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

Review 8.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

9.  A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system.

Authors:  Z Rekasi; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

Review 10.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.